Monoclonal Gammopathies of 'Neurological Significance': Paraproteinemic Neuropathies

被引:4
作者
Mani, Arun Mathai [1 ]
Devasia, Anup Joseph [2 ]
Nair, Aditya [1 ]
Benjamin, Rohit Ninan [1 ]
Prabhakar, Appaswamy Thirumal [1 ]
Sivadasan, Ajith [1 ]
Mathew, Vivek [1 ]
Aaron, Sanjith [1 ]
George, Biju [2 ]
Alexander, Mathew [3 ]
机构
[1] Christian Med Coll & Hosp, Dept Neurol Sci, Neurol Unit, Vellore, Tamil Nadu, India
[2] Christian Med Coll & Hosp, Dept Haematol, Vellore, Tamil Nadu, India
[3] Brunei Neurosci Stroke & Rehabil Ctr, Jerudong, Brunei
关键词
Paraproteinemic neuropathy; POEMS syndrome; Plasmacytoma; MGUS; Amyloid Neuropathy; PERIPHERAL-NERVE SOCIETY; JOINT TASK-FORCE; POEMS SYNDROME; EUROPEAN FEDERATION; LONG-TERM; POLYNEUROPATHY; PROGNOSIS; MANAGEMENT; CRITERIA; DEFINITIONS;
D O I
10.1017/cjn.2020.278
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To study the clinical profile and outcomes of patients with paraproteinemic neuropathy (PPN) and to explore the utility of nerve conduction studies (NCSs) to differentiate between the demyelinating subtypes. Methods: We did a retrospective analysis of patients diagnosed with PPN between January 2010 and December 2019 in an inpatient setting. The study population consisted of patients above 16 years of age presenting with clinical features suggestive of chronic peripheral neuropathy and on evaluation was found to have PPN. Results: A total of 74 patients were identified. The patients were predominantly in the 6th decade, and the majority were males. The subtypes of PPN were monoclonal gammopathy of undetermined significance (MGUS) (45.9%), POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes) (24.3%), solitary plasmacytoma (17.6%), multiple myeloma (8.1%), and AL amyloidosis (4.1%). There are specific features on NCS which can help in identifying POEMS syndrome and IgM MGUS. The majority of patients with PPN tend to stabilize or improve with treatment; however, many have a severe residual disability. New terminology and classification of these entities as 'monoclonal gammopathies of neurological significance' can aid in early diagnosis and the development of effective treatment, to prevent residual disability. Conclusion: PPN has a heterogeneous spectrum of clinical, biochemical, and electrophysiological features. NCS can help distinguish POEMS syndrome and IgM MGUS from other demyelinating subtypes.
引用
收藏
页码:616 / 625
页数:10
相关论文
共 50 条
  • [21] Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    Willrich, Maria A. V.
    Murray, David L.
    Kyle, Robert A.
    CLINICAL BIOCHEMISTRY, 2018, 51 : 38 - 47
  • [22] IgM monoclonal gammopathy-associated neuropathies with different IgM specificity
    Mata, S.
    Borsini, W.
    Ambrosini, S.
    Toscani, L.
    Barilaro, A.
    Piacentini, S.
    Sorbi, S.
    Lolli, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (08) : 1067 - 1073
  • [23] Ultrasound of the nerves - An appropriate addition to nerve conduction studies to differentiate paraproteinemic neuropathies
    Athanasopoulou, Ioanna M.
    Rasenack, Maria
    Grimm, Christine
    Axer, Hubertus
    Sinnreich, Michael
    Decard, Bernhard F.
    Grimm, Alexander
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 362 : 188 - 195
  • [24] Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients
    Gonzalez-Calle, Veronica
    Victoria Mateos, Maria
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2018, 58 : 57 - 63
  • [25] Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance
    Piot, J. M.
    Royer, M.
    Schmidt-Tanguy, A.
    Hoppe, E.
    Gardembas, M.
    Bourree, T.
    Hunault, M.
    Francois, S.
    Boyer, F.
    Ifrah, N.
    Renier, G.
    Chevailler, A.
    Audran, M.
    Chappard, D.
    Libouban, H.
    Mabilleau, G.
    Legrand, E.
    Bouvard, B.
    BLOOD CANCER JOURNAL, 2015, 5 : e345 - e345
  • [26] Monoclonal Gammopathies of Indetermined Significance: Diagnosis and Clinical Follow-up Guidelines
    Parreira, Joana
    Lucio, Paulo
    Joao, Cristina
    Macedo, Ana
    Sarmento, Ana Bela
    Geraldes, Catarina
    Goncalves, Cristina
    Esteves, Graca
    ACTA MEDICA PORTUGUESA, 2014, 27 (05): : 661 - 664
  • [27] Proposal and Validation of Prognostic Scoring Systems for IgG and IgA Monoclonal Gammopathies of Undetermined Significance
    Rossi, Francesca
    Petrucci, MariaTeresa
    Guffanti, Andrea
    Marcheselli, Luigi
    Rossi, Davide
    Callea, Vincenzo
    Vincenzo, Federico
    De Muro, Marianna
    Baraldi, Alessandra
    Villani, Oreste
    Musto, Pellegrino
    Bacigalupo, Andrea
    Gaidano, Gianluca
    Avvisati, Giuseppe
    Goldaniga, Maria
    DePaoli, Lorenzo
    Baldini, Luca
    CLINICAL CANCER RESEARCH, 2009, 15 (13) : 4439 - 4445
  • [28] Monoclonal Gammopathies and CKD Progression
    Chowdhury, Raad
    Gupta, Shruti
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 19 (03): : 280 - 282
  • [29] Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians
    Caers, Jo
    Vekemans, Marie-Christiane
    Bries, Greet
    Beel, Karolien
    Delrieu, Vanessa
    Deweweire, Anne
    Demuynck, Hilde
    De Prijck, Bernard
    De Samblanx, Hadewijch
    Kentos, Alain
    Meuleman, Nathalie
    Mineur, Philippe
    Offner, Fritz
    Vande Broek, Isabelle
    Van Droogenbroeck, Jan
    Vande Velde, Ann
    Wu, Ka Lung
    Delforge, Michel
    Schots, Rik
    Doyen, Chantal
    ANNALS OF MEDICINE, 2013, 45 (5-6) : 413 - 422
  • [30] Application of Capillary Electrophoresis in Monoclonal Gammopathies and the Cutoff Value of Monoclonal Protein in Differential Diagnosis of Multiple Myeloma and Other Monoclonal Gammopathies
    Cao, Fangfang
    Zhang, Rui
    Xu, Longqiang
    Liu, Mengyang
    Yuan, Yuan
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2021, 51 (03) : 400 - 407